These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1459463)

  • 1. Biphasic effect of Max on Myc cotransformation activity and dependence on amino- and carboxy-terminal Max functions.
    Prendergast GC; Hopewell R; Gorham BJ; Ziff EB
    Genes Dev; 1992 Dec; 6(12A):2429-39. PubMed ID: 1459463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral mutations enhance the Max binding properties of the vMyc b-HLH-LZ domain.
    Crouch DH; Fisher F; La Rocca SA; Goding CR; Gillespie DA
    Nucleic Acids Res; 2005; 33(16):5235-42. PubMed ID: 16166655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
    Min S; Mascarenhas NT; Taparowsky EJ
    Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of sequences responsible for the differential regulation of Myc function by delta Max and Max.
    Västrik I; Mäkelä TP; Koskinen PJ; Alitalo K
    Oncogene; 1995 Aug; 11(3):553-60. PubMed ID: 7630640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
    Davis LJ; Halazonetis TD
    Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation.
    Mäkelä TP; Koskinen PJ; Västrik I; Alitalo K
    Science; 1992 Apr; 256(5055):373-7. PubMed ID: 1566084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene-regulatory properties of Myc helix-loop-helix/leucine zipper mutants: Max-dependent DNA binding and transcriptional activation in yeast correlates with transforming capacity.
    Crouch DH; Fisher F; Clark W; Jayaraman PS; Goding CR; Gillespie DA
    Oncogene; 1993 Jul; 8(7):1849-55. PubMed ID: 8510929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.
    Fieber W; Schneider ML; Matt T; Kräutler B; Konrat R; Bister K
    J Mol Biol; 2001 Apr; 307(5):1395-410. PubMed ID: 11292350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
    Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
    Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites.
    Hurlin PJ; Quéva C; Eisenman RN
    Genes Dev; 1997 Jan; 11(1):44-58. PubMed ID: 9000049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic activity of the c-Myc protein requires dimerization with Max.
    Amati B; Brooks MW; Levy N; Littlewood TD; Evan GI; Land H
    Cell; 1993 Jan; 72(2):233-45. PubMed ID: 8425220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Myn, the murine homolog of max, with c-Myc stimulates methylation-sensitive DNA binding and ras cotransformation.
    Prendergast GC; Lawe D; Ziff EB
    Cell; 1991 May; 65(3):395-407. PubMed ID: 1840505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
    Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
    Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of Max: role of basic, helix-loop-helix/leucine zipper domains in DNA binding, dimerization and regulation of Myc-mediated transcriptional activation.
    Reddy CD; Dasgupta P; Saikumar P; Dudek H; Rauscher FJ; Reddy EP
    Oncogene; 1992 Oct; 7(10):2085-92. PubMed ID: 1408152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of transcription factors c-Myc, Max, and c-Myb by casein kinase II.
    Bousset K; Oelgeschläger MH; Henriksson M; Schreek S; Burkhardt H; Litchfield DW; Lüscher-Firzlaff JM; Lüscher B
    Cell Mol Biol Res; 1994; 40(5-6):501-11. PubMed ID: 7735324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the Myc and Max interaction specificity with lambda repressor-HLH domain fusions.
    Marchetti A; Abril-Marti M; Illi B; Cesareni G; Nasi S
    J Mol Biol; 1995 May; 248(3):541-50. PubMed ID: 7752223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overproduction of v-Myc in the nucleus and its excess over Max are not required for avian fibroblast transformation.
    Tikhonenko AT; Hartman AR; Linial ML
    Mol Cell Biol; 1993 Jun; 13(6):3623-31. PubMed ID: 8497274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NMR solution structure of a mutant of the Max b/HLH/LZ free of DNA: insights into the specific and reversible DNA binding mechanism of dimeric transcription factors.
    Sauvé S; Tremblay L; Lavigne P
    J Mol Biol; 2004 Sep; 342(3):813-32. PubMed ID: 15342239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Casein kinase II inhibits the DNA-binding activity of Max homodimers but not Myc/Max heterodimers.
    Berberich SJ; Cole MD
    Genes Dev; 1992 Feb; 6(2):166-76. PubMed ID: 1737614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The N-myc oncoprotein is a transcriptional activator and associates with max and RB1 proteins.
    Wenzel A; Cziepluch C; Schürmann J; Schwab M
    Prog Clin Biol Res; 1994; 385():59-66. PubMed ID: 7972238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.